AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
$207B Market Shift: The Race for Fast Track Approval in Oncology
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: LaChapelle Robin
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: Lutzker Stuart
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: Kung Winston
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: Yao Zhengbin
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: Kastenmayer James Paul
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.